Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC)

Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC)

Bibliographic Details
Main Authors: L.C.V. Thomsen, A. Honoré, B. Almås, L.A.R. Reisæter, K. Førde, E.K. Kristoffersen, S.H. Kaada, G.K. Melve, S.I. Helle, G. Kvalheim, W. Azeem, J.R. Olsen, O.J. Halvorsen, L.A. Akslen, D. Bahn, K. Pantel, S. Riethdorf, H. Ragde, B.T. Gjertsen, A.M. Øyan, K.H. Kalland, C. Beisland
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320338428

Internet

http://www.sciencedirect.com/science/article/pii/S2666168320338428

Similar Items